ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
about
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyHepatitis C virus: Virology, diagnosis and treatmentLimiting the access to direct-acting antivirals against HCV: an ethical dilemma.Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.SASLT guidelines: Update in treatment of Hepatitis C virus infection.Drug interactions with new hepatitis C oral drugs.Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Beclabuvir for the treatment of hepatitis C.Asunaprevir for hepatitis C: a safety evaluation.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.New hepatitis C therapies for special patient populations.
P2860
Q26775825-101FE2AF-7B30-445F-B9AA-BA253A110A12Q26782405-E1AAB770-9BD1-439F-AAFE-8560B7B775DCQ28082000-375C3689-DF00-49D1-888D-549C8F48043CQ30244361-188A933F-A6B2-4E58-8494-904D5AF09790Q36806650-54EF01DB-F23F-40FF-B02C-C5B63FF93BDCQ37216507-062490E9-E5EF-442C-AFC9-AB5048F1E131Q38305640-7E6CFCB8-2EB4-4FF3-90A4-9AB79F6219AFQ38355057-7AC40B9F-E3AE-42AE-9212-4E458218A8AEQ38387667-4CE14A89-3489-41F0-A63A-D2210CA6C624Q38544196-6967B05D-C352-474E-A2A3-1CA4D8F00CBFQ38578458-73E05CD5-635F-47C2-8A67-0FDCEBAFF6B8Q38824198-81111409-4B41-4D3B-8FF0-A07DC373A94FQ38826176-9E282007-7734-4B23-B84E-7F29C268E824Q39900651-B7FFBFAF-A621-4BD5-B474-51117A789E2AQ40899794-17BD1CD3-987D-4EE3-A6E4-429912E201CD
P2860
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
@en
type
label
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
@en
prefLabel
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
@en
P50
P1476
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
@en
P2093
Federico Borgia
Guglielmo Borgia
P304
P356
10.2174/0929867321666140706125950
P577
2014-01-01T00:00:00Z